- Home
- IMMX vs ANVS Comparison
IMMX vs ANVS Comparison
Compare IMMX & ANVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMMX
- ANVS
- Stock Information
- Founded
- IMMX 2014
- ANVS 2008
- Country
- IMMX United States
- ANVS United States
- Employees
- IMMX N/A
- ANVS N/A
- Industry
- IMMX Medicinal Chemicals and Botanical Products
- ANVS Biotechnology: Pharmaceutical Preparations
- Sector
- IMMX Health Care
- ANVS Health Care
- Exchange
- IMMX Nasdaq
- ANVS Nasdaq
- Market Cap
- IMMX 61.1M
- ANVS 55.5M
- IPO Year
- IMMX 2021
- ANVS 2020
- Fundamental
- Price
- IMMX $2.65
- ANVS $2.51
- Analyst Decision
- IMMX Strong Buy
- ANVS Strong Buy
- Analyst Count
- IMMX 1
- ANVS 4
- Target Price
- IMMX $7.00
- ANVS $18.00
- AVG Volume (30 Days)
- IMMX 220.7K
- ANVS 341.6K
- Earning Date
- IMMX 08-11-2025
- ANVS 08-14-2025
- Dividend Yield
- IMMX N/A
- ANVS N/A
- EPS Growth
- IMMX N/A
- ANVS N/A
- EPS
- IMMX N/A
- ANVS N/A
- Revenue
- IMMX N/A
- ANVS N/A
- Revenue This Year
- IMMX N/A
- ANVS N/A
- Revenue Next Year
- IMMX N/A
- ANVS N/A
- P/E Ratio
- IMMX N/A
- ANVS N/A
- Revenue Growth
- IMMX N/A
- ANVS N/A
- 52 Week Low
- IMMX $1.26
- ANVS $1.11
- 52 Week High
- IMMX $3.20
- ANVS $10.54
- Technical
- Relative Strength Index (RSI)
- IMMX 49.64
- ANVS 45.90
- Support Level
- IMMX $2.63
- ANVS $2.63
- Resistance Level
- IMMX $3.20
- ANVS $3.00
- Average True Range (ATR)
- IMMX 0.22
- ANVS 0.22
- MACD
- IMMX -0.04
- ANVS -0.02
- Stochastic Oscillator
- IMMX 3.51
- ANVS 23.44
About IMMX Immix Biopharma Inc.
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.
About ANVS Annovis Bio Inc.
Annovis Bio Inc is a clinical-stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neurodegenerative diseases. The pipeline products of the company consists of: Buntanetap for chronic neurodegeneration - including AD and PD; ANVS405 for acute neurodegeneration; and ANVS301 for AD.